NXTC vs. MNMD, ABUS, EOLS, RLAY, KROS, DNA, TYRA, PGEN, ARVN, and TBPH
Should you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Mind Medicine (MindMed) (MNMD), Arbutus Biopharma (ABUS), Evolus (EOLS), Relay Therapeutics (RLAY), Keros Therapeutics (KROS), Ginkgo Bioworks (DNA), Tyra Biosciences (TYRA), Precigen (PGEN), Arvinas (ARVN), and Theravance Biopharma (TBPH). These companies are all part of the "pharmaceutical products" industry.
NextCure vs. Its Competitors
NextCure (NASDAQ:NXTC) and Mind Medicine (MindMed) (NASDAQ:MNMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.
NextCure presently has a consensus price target of $33.00, indicating a potential upside of 561.32%. Mind Medicine (MindMed) has a consensus price target of $25.50, indicating a potential upside of 187.16%. Given NextCure's higher possible upside, analysts plainly believe NextCure is more favorable than Mind Medicine (MindMed).
In the previous week, NextCure had 2 more articles in the media than Mind Medicine (MindMed). MarketBeat recorded 3 mentions for NextCure and 1 mentions for Mind Medicine (MindMed). Mind Medicine (MindMed)'s average media sentiment score of 0.00 beat NextCure's score of -0.33 indicating that Mind Medicine (MindMed) is being referred to more favorably in the news media.
42.7% of NextCure shares are owned by institutional investors. Comparatively, 27.9% of Mind Medicine (MindMed) shares are owned by institutional investors. 13.3% of NextCure shares are owned by insiders. Comparatively, 2.3% of Mind Medicine (MindMed) shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Mind Medicine (MindMed)'s return on equity of -40.33% beat NextCure's return on equity.
Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.
NextCure has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Mind Medicine (MindMed) has a beta of 2.45, suggesting that its share price is 145% more volatile than the S&P 500.
Summary
Mind Medicine (MindMed) beats NextCure on 8 of the 14 factors compared between the two stocks.
Get NextCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NextCure Competitors List
Related Companies and Tools
This page (NASDAQ:NXTC) was last updated on 7/21/2025 by MarketBeat.com Staff
